Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Properties remain in Diös’ ownership

The financing reservation regarding the previously communicated divestment of six mixed properties to Point Properties AB was not met. Therefore the transaction is not completed and the properties remain in Diös’ ownership.The sale affects properties in Gävle, Falun, Umeå och Skellefteå. The agreement was communicated on March 25 and was subject to a financing reservation that has not been met. The properties are fully let and Diös are looking forward to continue to manage and develop them in each city. For further information please contact:Knut Rost, CEO, DiösTelephone: +46 (0)10-

The Board of Directors of Prostatype Genomics AB decides on a previously communicated rights issue of units

The Board of Directors of Prostatype Genomics AB (”Prostatype Genomics” or the “Company”) has today, the 23[ ]June 2022, decided to execute an issue of units (shares and attached free-of-charge warrants) with preferential right for existing shareholders, where also the general public is able to participate (“the Rights Issue”). The decision on the Rights Issue was made with support by an authorization from the Annual General Meeting held on the 2[ ]June 2022 in accordance with the proposal made by the Board, which was communicated through a press release on the 2 May 2022. The Rights Issue

SpectrumOne fastställer avstämningsdag för utdelning av aktier i Observit AB (publ)

Den 31 mars 2022 beslutade extra bolagsstämman i SpectrumOne AB (”SpectrumOne”) att dela ut 374 220 904 aktier i Observit AB (publ) (”Observit”) till SpectrumOnes aktieägare. Styrelsen bemyndigades samtidigt att fastställa avstämningsdag för utdelningen. Avstämningsdagen har som tidigare kommunicerats satts till den 30 juni 2022 och detta datum har nu slutligen fastställts. En aktie i SpectrumOne berättigar till en aktie i Observit. Utöver att vara registrerad som aktieägare i SpectrumOne på avstämningsdagen för utdelningen behöver aktieägare inte vidta några åtgärder för att erhålla aktier

Adelis acquires IT company netIP

The Danish IT company netIP A/S (”netIP”) partners with Adelis Equity Partners (“Adelis”) to support the company’s next growth phase.netIP, which is a leading and independent one-stop-shop IT provider, has a special focus on IT outsourcing, IT infrastructure, IT security, SharePoint and IT consulting services for Danish businesses. In the past five years, the number of employees has doubled to the current 165 employees based in seven departments in Thisted, Holstebro, Herning, Aalborg, Aarhus, Viborg and Herlev. “In the past year, netIP has completed a successful turnaround after an

Atrium Ljungberg is hosting a presentation of Q2 Report 2022 on 8 July at 10.00 CET

Atrium Ljungberg is hosting an online broadcast of the Q2 Report 2022 presentation at 10.00 CET on 8 July 2022. The Q2 report 2022 will be published at 7.30 CET on the same day.Equity analysts, investors, media and other stakeholders are invited to participate in the conference where CEO Annica Ånäs and CFO Ulrika Danielsson will present the results for Q2 2022. The presentation will be held in English and can be watched online using the following link: https://tv.streamfabriken.com/en-atrium-ljungberg-q2-2022 After the broadcast, the presentation and written material can be accessed on

Scandinavian ChemoTech provides a status report and wishes everyone a pleasant midsummer and holiday

It has been full speed ahead for both Human and Animal Care during the first 6 months of the year, which has been filled with both clinical progress and the establishment of new partners for the two business areas.We have soon gone through half of 2022, which has been filled with some of the Company's greatest successes.   At the end of 2021, the Company shifted its focus to marketing and sales measures within Animal Care. Although it has not yet resulted in any major sales progress, we are fully convinced that this was a wise decision that will benefit the Company's cash flow in a

Casino Sites Forms Collaboration with Buzz Bingo Casino

Casino Sites is thrilled to announce that it has developed a new and exciting partnership with online casino site brand, Buzz Bingo Casino.The deal will see Buzz Bingo Casino added to the network of casino suppliers featured on casinosites.ltd.uk, promoting the brand's exclusive offers and games inventory to the platform's burgeoning player community. Casino Sites is famed for working with new casino sites and industry innovators like Buzz Bingo Casino. Its comprehensive list of partners encompasses a vast selection of casinos to suit all player appetites, making it one of the most

SOFTSWISS Game Aggregator Wins at EGR B2B Awards 2022

SOFTSWISS is delighted to announce that its Game Aggregator has claimed Aggregator platform of the Year! One of the most demanded products in the company portfolio outperformed its competitors and became the winner of the EGR B2B Awards 2022.Although SOFTSWISS has a collection of professional accolades for its innovative solutions and expert services, this is the first time the company got a reputable trophy from the EGR team. Being among the most prestigious industry competitions, the annual EGR B2B Awards recognises the achievements in different fields of iGaming.  With its simple one-

BioStock studio: BioInvent and CASI on their collaboration

In a BioStock Studio exclusive, Martin Welschof, CEO of BioInvent and Wei-Wu He, Chairman and CEO of the American biopharma company CASI Pharmaceuticals, joined the programme to talk about the collaboration between the two companies around the development of drug candidate BI-1206. Among other things, they discussed the reasons behind CASI chosing to partner with BioInvent, the market potential for BI-1206 and the next clinical development step for the candidate.Watch the interview with Martin Welschof and Wei-Wu He at biostock.se: https://www.biostock.se/en/2022/06/bioinvent-and-casi-on-

Announcing partnership as Venture Developer to Traders Alloy AB to promote Open Finance

Katalysen Ventures is pleased to announce that we have formed a partnership as a late co-founder and venture developer to Stockholm-based Open Finance venture Traders Alloy AB. Katalysen Ventures has been invited to participate as a late co-founder and to invest approximately €117 (SEK1250) at par value (swedish: nominellt värde) in return for a 5% equity stake. Additionally, as a venture developer, Katalysen Ventures will help Traders Alloy find optimal product-market fit and secure key partnerships and clients. For this work as a venture developer, Katalysen will receive long-term options (

XMReality receives order from Coor

XMReality has received an order from Coor, a leading provider of Facility Management services in the Nordic region, for licenses of XMReality Remote Guidance. The contract is a subscription agreement with automatic renewal. The main area of use is maintenance within Facility Management and to begin with, the service will be used for the Swedish market.“This is another customer in Facility Management, an area where we are seeing increased demand. The order is thus in line with our strategic focus on becoming strong in this particular vertical. We have very recently attended one of Coor's

BETSSON ANNOUNCES THAT THE CONDITION FOR THE EARLY REDEMPTION OF BONDS OF SERIES 2019/2022 HAS BEEN FULFILLED

2022-06-23 On 21 June 2022, Betsson AB (publ) (the “Company”) provided notice that it intends to redeem in full the outstanding bonds of series 2019/2022 with ISIN SE0013110814 (the “Early Redemption” and the “Bonds”, respectively).   The Early Redemption was conditional upon successful settlement of the Company’s issue of new bonds, as further described in the Company’s press release on 15 June 2022. This condition has been fulfilled and the Early Redemption is therefore no longer conditional. The Early Redemtion will hence occur on 18 July 2022 and the redemption amount will be

RaySearch releases RayCare 6A

RaySearch Laboratories AB (publ) announces the release of the latest version of RayCare®*, the next generation oncology information system. RayCare 6A adds important enhancements to all major areas of the product, and introduces enhanced connectivity with other hospital information systems, improving flow of data between systems.RayCare 6A brings several improvements to the patient chart, including usability and efficiency enhancements such as user configured templates for selected workspaces. A new patient chart feature provides support for financial accounts for charge capture.

Tobii Dynavox acquires ASK in Denmark

Tobii Dynavox , the world leader in assistive technology for communication, has agreed to acquire all business activities and assets of its reselling partner ASK  in Denmark, effective July 1. The acquisition brings Tobii Dynavox closer to its customers in the Danish market, supporting people with communication disabilities more effectively.  ASK is a supplier of assistive technology products and services to customers in Denmark, including municipalities, schools, communication centers, care centers and other institutions. The Tobii

Inhalation Sciences signs new IRS contract with returning customer

(Stockholm 23 June 2022) Inhalation Research Services (IRS), ISAB’s contract research organization, has signed a contract worth 581,000 SEK with a returning customer following a previous successful research project in February 2022.The customer will once again be using ISAB’s in vivo intratracheal exposure module which delivers voluminous data with exceptionally high precision. Unlike conventional ‘tower testing’ technologies it delivers aerosol directly to the lungs of an individual test rodent, bypassing its nose, whilst carefully monitoring aerosol concentration and individual breathing

Keliber reports maiden mineral resource estimate for new Tuoreetsaaret deposit

Keliber has discovered a new lithium deposit, Tuoreetsaaret, located between the Rapasaari and Syväjärvi deposits. The maiden Mineral Resource estimate for the Tuoreetsaaret deposit was completed in June 2022. The Mineral Resources (all Inferred) of Tuoreetsaaret are 1.41 million tonnes with an average grade of 0.70% Li₂O, which increases Keliber’s total Mineral Resources by 9 percent, to 17.03 million tonnes (previously 15.62 million tonnes). Keliber's Mineral Resource estimate for the new Tuoreetsaaret lithium deposit comply with the JORC 2012 code. Keliber’s press release is

YIT, the City of Helsinki, and Senate Properties have signed a settlement agreement to close the Trigoni project

YIT Corporation Press release 23 June 2022 at 2:00 p.m.Senate Properties and the City of Helsinki, as owners and sellers of the property, and YIT, as the buyer of the property and project contractor, have agreed by mutual consent to terminate the Implementation Contract concerning the Start-Up Area of the Central Pasila high-rise area and the related preliminary contract on the sale of the property signed on 8 February 2019. As a result of the Settlement Contract now signed on 22 June 2022, the obligations of the parties under the Contracts will terminate on mutually agreed terms. "It is

Preliminary results of SRV Group Plc’s successful rights issue and directed share issue

SRV GROUP PLC INSIDE INFORMATION   23 JUNE 2022 AT 14.00 EESTPreliminary results of SRV Group Plc’s successful rights issue and directed share issueNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.The subscription period for SRV Group Plc’s (“SRV”) rights issue (the “Offering”) ended on 21 June 2022. According to the preliminary results of the Offering, a total of 373,168,967 offer shares (the “Offer Shares”) were subscribed for

Mineral Resources from Keliber’s New Tuoreetsaaret Lithium Deposit

Keliber has discovered a new lithium deposit, Tuoreetsaaret, located between the Rapasaari and Syväjärvi deposits. The maiden Mineral Resource estimate for the Tuoreetsaaret deposit was completed in June 2022. The Mineral Resources (all Inferred) of Tuoreetsaaret are 1.41 million tonnes with an average grade of 0.70% Li₂O, which increases Keliber’s total Mineral Resources by 9 percent, to 17.03 million tonnes (previously 15.62 million tonnes).Keliber initiated the exploration campaign at the Tuoreetsaaret area in March 2020. The deposit is located next to the future concentrator plant.

New opportunities for Brighter in the Kingdom of Saudi Arabia

Brighter AB (Publ) ("Brighter") announced today that the Communications and Information Technology Commission (CITC) has invited Brighter to apply for possible participation in the Emerging Technologies Regulatory Sandbox in the Kingdom of Saudi Arabia (KSA).  In line with KSA’s Vision 2030, the Communications and Information Technology Commission (CITC) has launched the Emerging Technologies Regulatory Sandbox to support investors and companies interested in the Kingdom’s emerging tech field. The Regulatory Sandbox aims to increase investment, foster innovation, maintain effective

Report from the Annual General Meeting of Shareholders of DDM Holding AG

DDM Holding AG (First North Growth Market: DDM), (the “Company”), held its Annual General Meeting (the “AGM”) today, 23 June 2022, in Zürich, Switzerland. A summary of the AGM resolutions is presented below.Minutes of the AGM The minutes of the AGM, including a complete account of all resolutions taken, will be available on the Company’s website http://ddm-group.ch/investors within a few days. Election of the chairman for the day Following the board of directors’ proposal, the AGM approved to elect Fredrik Olsson, Chief Financial Officer of DDM Holding AG as chairman for the day.

Sinch receives a tier one ranking in ROCCO’s latest reports for its A2P Monetization product suite and its SMS Firewall product for MNOs, and A2P SMS products for enterprises

Sinch Ranked Tier One by ROCCO [Sinch ranked Tier 1 in ROCCO's latest reports for SMS Firewall and A2P SMS Vendors] Sinch ranked Tier 1 in ROCCO's latest reports for SMS Firewall and A2P SMS Vendors Stockholm, Sweden –  23 June 2022 – Sinch AB (publ), a global leader in cloud communications and mobile customer engagement, today announced that it has been awarded the highest ‘Tier One’ ranking in recent reports from Roaming Consulting Company (ROCCO) for its Application-to-Person (A2P) SMS Monetization suite and A2P SMS Firewall product for MNOs, and A2P SMS products for enterprises,

Edeka Schwebel - a climate-neutral success project in the middle of Frankenberg

· Climate-friendly conversion and modernization of the Edeka market with refrigeration solutions from Viessmann · CO2 emissions saved in the order of around 310 mid-range cars over the next 12 years through the use of sustainable refrigerants · Edeka store part of the "Climate-neutral Waldeck-Frankenberg - Mission Zero" initiativeThe EDEKA market Schwebel (formerly Lebensmittelhaus Schwebel) in the center ofFrankenberg was established in the early 1950s. Three generations of the family have beenoffering and selling food, beverages, and other products for daily life here. The

Cyxone files regulatory submission to start clinical phase 2b study with Rabeximod

Cyxone (publ), a biotech company in autoimmune diseases, today filed a submission to the National Institute of Pharmacy and Nutrition (OGYEI) - the Hungarian Medical Product Agency - for approval to start a clinical phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA). This first submission will be followed by applications to relevant regulatory authorities in other European countries.The submission to the Hungarian Regulatory Authority OGYEI for approval to start a clinical phase 2b trial with Cyxone’s drug candidate

There are no items matching the current filter
There are no more items matching the current filter
Back to top